A cell-based beta-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication |
| |
Authors: | Zuck Paul Murray Edward M Stec Erica Grobler Jay A Simon Adam J Strulovici Berta Inglese James Flores Osvaldo A Ferrer Marc |
| |
Institution: | Department of Automated Biotechnology, Merck and Co., 502 Louise Lane., North Wales, PA 19454, USA. paul_zuck@merck.com |
| |
Abstract: | This report describes the development, optimization, and implementation of a cell-based assay for high-throughput screening (HTS) to identify inhibitors to hepatitis C virus (HCV) replication. The assay is based on a HCV subgenomic RNA replicon that expresses beta-lactamase as a reporter for viral replication in enhanced Huh-7 cells. The drug targets in this assay are viral and cellular enzymes required for HCV replication, which are monitored by fluorescence resonance energy transfer using cell-permeable CCF4-AM as a beta-lactamase substrate. Digital image processing was used to visualize cells that harbor viral RNA and to optimize key assay development parameters such as transfection and culturing conditions to obtain a cell line which produced a robust assay window. Formatting the assay for compound screening was problematic due to small signal-to-background ratio and reduced potency to known HCV inhibitors. These technical difficulties were solved by using clavulanic acid, an irreversible inhibitor of beta-lactamase, to eliminate residual beta-lactamase activity after HCV replication was terminated, thus resulting in an improved assay window. HTS was carried out in 384-well microplate format, and the signal-to-background ratio and Z factor for the assay plates during the screen were approximately 13-fold and 0.5, respectively. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|